Humoral response against myelin associated glycoprotein reflects oligodendroglial degeneration in Parkinson’s disease

Ewa Papuć 1  ,  
Department of Neurology, Medical University of Lublin, Poland
Chair and Department of Clinical Immunology, Medical University of Lublin, Poland
Ann Agric Environ Med 2016;23(2):390–393
Identification of disease-specific diagnostic and prognostic biomarkers which would enable early detection and follow-up of Parkinson’s disease (PD) is a crucial problem. Recently, we confirmed the presence of adaptive immune response against different glial-derived antigens in PD.

The aim of the study was to assess humoral response against myelin-associated glycoprotein (MAG) on a larger group of PD patients. IgM autoantibodies against MAG were measured by an ELISA system in 66 PD patients and 66 control subjects.

The study confirmed a significantly increased production of anti-MAG IgM antibodies in parkinsonian patients (p<0.05). No correlations were found between anti-MAG IgM antibody titers and disease severity measured on the Hoehn-Yahr scale, MMSE or age of PD onset (p>0.05). The results provide evidence for activation of humoral response against MAG in PD patients, but argue against the utility of anti-MAG antibodies as biomarkers of disease severity. The results additionally indicate the potential protective role of autoimmunity in maintaining the body’s homeostasis, which may involve the clearance of abnormal proteins. Further studies are necessary to confirm the role of anti-MAG antibodies as biomarkers of PD, especially in relation to other neurodegenerative disorders.

Ewa Papuć   
Department of Neurology, Medical University of Lublin, Poland
1. Monahan AJ, Warren M, Carvey PM.Neuroinflammation and peripheral immune infiltration in Parkinson’s disease: an autoimmune hypothesis. Cell Transplant. 2008; 17: 363–367.
2. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, et al. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. J Alzheimers Dis. 2008; 26: 171–179.
3. Yanamandra K, Gruden M, Casaite Y, Meskys R, Forsgren L, Morozova-Roche L. a-Synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson’s disease patients. PLoS 2011; 25: e18513.
4. Martino D, Church A, Giovannoni G. Are antibasal ganglia antibodies important, and clinically useful? Pract Neurol. 2007; 7: 32–41.
5. Berger T, Rubner P, Schautzer F, Egg R, Ulmer H, Mayringer I, Dilitz E, Deisenhammer F, Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med. 2003; 349: 139–145.
6. Pihan M, Decaux O, Marcorelles P, Bahon-Riedinger I, Lemercier S, Gainche-Salmon A, Doncker AV. Neuropathies associated with monoclonal IgM anti-MAG antibodies. Rev Med Interne. 2012; 33: 686–92. doi: 10.1016/j.revmed.2012.05.009.
7. Magy L, Kaboré R, Mathis S, Lebeau P, Ghorab K, Caudie C, Vallat JM. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies. J Immunol Res. 2015: 450391. doi: 10.1155/2015/450391.
8. Maetzler W, Berg D, Synofzik M, Brockmann K, Godau J, Melms A, Gasser T, Hörnig S, Langkamp M. Autoantibodies Against Amyloid and Glial-Derived Antigens are Increased in Serum and Cerebrospinal Fluid of Lewy Body-Associated Dementias. J Alzheimers Dis. 2011; 26: 171–179.
9. Gruden MA, Davidova TB, Malisauskas M, Sewell RD, Voskresenskaya NI, WilhelmK et al. Differential neuroimmune markers to the onset of Alzheimer’s disease neurodegeneration and dementia: autoantibodies to Abeta ((25–35)) oligomers, S100b and neurotransmitters. J Neuroimmunol. 2007; 186: 181–192.
10. Papachroni KK, Ninkina N, Papapanagiotou A, Hadjigeorgiou GM, Xiromerisiou G, et al. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem. 20007; 101: 749–756.
11. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, et al. Naturally occurring alpha-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 2013; 80: 169–75.
12. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. ActaNeuropathol. (Berl) 2000; 99: 14–20.
13. Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease. Brain Pathol. 2013; 23: 263–273.
14. Papuć E, Kurzepa J, Kurys-Denis E, Grabarska A, Krupski W, Rejdak K. Humoral response against glial derived antigens in Parkinson’s disease. Neurosci Lett. 2014; 566: 77–81.
15. Maetzler W, Apel A, Langkamp M, Deuschle C, Dilger SS, Stirnkorb JG, et al. Comparable autoantibody serum levels against amyloid-and inflammation associated proteins in Parkinson’s disease patients and controls. PLoS One 2014; 21:e88604. doi: 10.1371/journal.pone.0088604.
16. Koehler NK, Stransky E, Shing M, Gaertner S, Meyer M, et al. Altered Serum IgG Levels to alpha-Synuclein in Dementia with Lewy Bodies and Alzheimer’s Disease. PLoS One 2013; 8: e64649.
17. Papuć E, Kurys-Denis E, Krupski W, Tatara M, Rejdak K. Can Antibodies Against Glial Derived Antigens be Early Biomarkers of Hippocampal Demyelination and Memory Loss in Alzheimer’s Disease? J Alzheimers Dis. 2015; 28: 115–121. doi: 10.3233/JAD-150309.
18. Nguyen T, Mehta NR, Conant K, Kim KJ, Jones M, Calabresi PA, et al. Axonal protective effects of the myelin associated glycoprotein. J Neurosci. 2009; 29: 630– 637.
19. Thompson HJ, Marklund N, LeBold DG, Morales DM, Keck CA, Vinson M, et al. Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody. Eur J Neurosci. 2006; 24: 3063–3072.
20. Irving EA, Vinson M, Rosin C, Roberts JC, Chapman DM, Facci L, et al. Identification of neuroprotective properties of anti-MAG antibody: a novel approach for the treatment of stroke? J Cereb Blood Flow Metab. 2005; 25: 98–107.
21. DeMattos RB, Bale KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci. USA 2001; 98: 8850–8855.
22. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015; 30: 1591–1601. doi: 10.1002/mds.26424.
23. Burke RE, Dauer WE, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol. 2008; 64: 485–491. doi: 10.1002/ana.21541.
24. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24: 197–111.
25. Temajo NO, Howard N. The virus-induced HSPs regulate the apoptosis of operatus APCs that results in autoimmunity, not in homeostasis. See comment in PubMed Commons below Autoimmun Rev. 2014; 13: 1013–1019.
26. Overmyer M, Helisalmi S, Soininen S, Laakso M, Riekkinen P, Alafuzoff I. Reactive microglia in aging and dementia: an immunohistochemical study of postmortem human brain tissue, Acta Neuropathol. (Berl) 1999; 97: 383–392.
Copy url